15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Briacell Therapeutics Corp, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $40.00 to $40.00, so the covering firms are broadly aligned. The average target of $40.00 sits 972% above the current $3.73. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-4.84 next quarter toward $-3.40 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Briacell Therapeutics Corp.
As of Jul, 1 of 1 firms rate BCTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BCTX EPS & revenue forecast
EPS · NEXT QUARTER
$-4.84
Range $-4.84 – $-4.84 · 1 analysts · -79% YoY
Next period, 1 analysts expect Briacell Therapeutics Corp to earn $-4.84 a share (range $-4.84 – $-4.84), versus $-23.30 a year earlier. , growing to $-3.40 the year after.
REVENUE · NEXT QUARTER
—
Range — – — · 1 analysts
Revenue is expected to reach — (range — – —). Full-year consensus is $0, rising to $10.1M next year.
Top analysts covering Briacell Therapeutics Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BCTX.
#1
Emily Bodnar
HC Wainwright & Co. · Rank #396
Buy
$40.00+972.4% to target
Overall win rate
23%
+ Follow
BCTX stock forecast FAQ
What is BCTX's average 12-month price target?+
The 1 analysts with a live target average $40.00 for Briacell Therapeutics Corp over the next 12 months, ranging from a $40.00 high to a $40.00 low.
Is BCTX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover BCTX?+
1 analysts have an active rating on Briacell Therapeutics Corp, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering BCTX?+
Among analysts who currently cover BCTX, Emily Bodnar of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #396). Their current call is Buy with a $40.00 target.
What is Briacell Therapeutics Corp's projected EPS for next quarter?+
The consensus estimate is $-4.84 per share (range $-4.84 – $-4.84) across 1 analysts. Full-year EPS is projected at —, rising to $-3.40 the following year.
How much revenue is Briacell Therapeutics Corp expected to report next quarter?+
Consensus revenue is — (range — – —). Full-year revenue is projected at $0, growing to $10.1M next year.
Have analysts been upgrading or downgrading BCTX lately?+
As of Jul, 1 of 1 firms rate BCTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BCTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
